AcelRx Makes Headway With Second Pain Drug-Device Combo

With its lead drug candidate Zalviso in US FDA limbo, AcelRx Pharmaceuticals is focused on its other late-stage pain drug ARX-04, a health care professional-administered sublingual tablet that delivered fast relief of moderate-to-severe post-surgical pain for patients enrolled in a Phase III clinical trial.

With its lead drug candidate Zalviso in US FDA limbo, AcelRx Pharmaceuticals is focused on its other late-stage pain drug ARX-04, a health care professional-administered sublingual tablet that delivered fast relief of moderate-to-severe post-surgical pain for patients enrolled in a Phase III clinical trial.

The Redwood City, California-based company plans to initiate a second Phase III trial during the third quarter of this year...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Neurological

More from Therapeutic Category